Capricor Therapeutics, Inc.

CAPR · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders9.4%

Institutions76.0%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	$22.27M	$25.18M	$244898	$310250	$1.01M	$1.67M	$2.67M	$4.00M	$5.52M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$108.14M	-$42.56M	-$24.08M	-$20.94M	-$13.69M	-$7.73M	-$15.33M	-$12.86M	-$16.98M	-$12.61M
Operating income as a percentage of revenue.	–	-191.1%	-95.6%	-8549.9%	-4412.6%	-769.5%	-917.0%	-482.4%	-424.6%	-228.6%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$105.04M	-$40.47M	-$22.29M	-$20.02M	-$13.66M	-$7.64M	-$15.19M	$2.43M	-$18.81M	-$12.86M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.00	$-1.00	$0.00	$-0.87	$-0.88	$-2.00	$0.00	$0.00	$-1.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.00	$-1.00	$0.00	$-0.87	–	–	$0.00	$0.00	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$287.85M	$11.29M	$14.69M	$34.90M	$32.67M	$3.90M	$4.26M	$6.14M	$3.20M	$5.57M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$355.95M	$170.48M	$58.73M	$41.33M	$34.62M	$11.11M	$9.25M	$16.27M	$18.75M	$16.07M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	$3.38M	$0	$246689	–	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$50.16M	$25.02M	$36.13M	$9.96M	$6.42M	$4.27M	$4.63M	$5.05M	$22.75M	$17.10M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$305.79M	$145.46M	$22.60M	$31.37M	$28.20M	$6.84M	$4.62M	$11.23M	-$4.00M	-$1.03M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$69.81M	-$40.00M	-$25.60M	-$16.81M	-$10.05M	-$6.82M	-$13.86M	-$14.23M	-$15.80M	-$10.82M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$2.90M	$1.17M	$1.31M	$1.20M	$547601	$0	$316486	$32185	$191970	$129697
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$72.72M	-$41.16M	-$26.91M	-$18.01M	-$10.60M	-$6.82M	-$14.18M	-$14.26M	-$15.99M	-$10.95M

	You	Peer avg
Revenue Growth	–	+114.2%
ROE	-73.7%	-113.4%

Capricor Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison